Rania El Botty

1.3k total citations
23 papers, 334 citations indexed

About

Rania El Botty is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Rania El Botty has authored 23 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in Rania El Botty's work include Advanced Breast Cancer Therapies (4 papers), Chromatin Remodeling and Cancer (3 papers) and Cancer Cells and Metastasis (3 papers). Rania El Botty is often cited by papers focused on Advanced Breast Cancer Therapies (4 papers), Chromatin Remodeling and Cancer (3 papers) and Cancer Cells and Metastasis (3 papers). Rania El Botty collaborates with scholars based in France, Syria and United Kingdom. Rania El Botty's co-authors include Elisabetta Marangoni, Ivan Bièche, Sophie Vacher, Sophie Château‐Joubert, Sergio Roman‐Roman, Jean‐Luc Servely, Florence Coussy, Dalila Labiod, Ludmilla de Plater and Franck Assayag and has published in prestigious journals such as Molecular Cell, Biomaterials and Cancer Research.

In The Last Decade

Rania El Botty

21 papers receiving 332 citations

Peers

Countries citing papers authored by Rania El Botty

Since Specialization

Citations

This map shows the geographic impact of Rania El Botty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rania El Botty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rania El Botty more than expected).

Fields of papers citing papers by Rania El Botty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rania El Botty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rania El Botty. The network helps show where Rania El Botty may publish in the future.

Co-authorship network of co-authors of Rania El Botty

This figure shows the co-authorship network connecting the top 25 collaborators of Rania El Botty. A scholar is included among the top collaborators of Rania El Botty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rania El Botty. Rania El Botty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers	Cancer Letters	Sylvie Rodrigues-Ferreira, Rania El Botty et al.	1
2	Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study	Cancer Research Communications	William C. Reinhold, Elisabetta Marangoni et al.	1
3	Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors	Molecular Cell	Daniele Musiani, Hatice Yücel et al.	3
4	Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients	Cancers	Didier Decaudin, Fariba Némati et al.	0
5	Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers	Cancer Research	Marjan Iravani, Rania El Botty et al.	6
6	HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers	Molecular Oncology	Rania El Botty, Sophie Vacher et al.	5
7	In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts	Frontiers in Oncology	Thibault Passeri, Ahmed Dahmani et al.	10
8	Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft	Cancers	Thibault Passeri, Ahmed Dahmani et al.	17
9	Abstract LB567: Dramatic in vivo efficacy of the EZH2-inhibitor tazemetostat in PBRM1-mutated human chordoma xenograft	Cancer Research	Thibault Passeri, Ahmed Dahmani et al.	1
10	Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant	Breast Cancer Research	Julien Jacquemetton, Loay Kassem et al.	12
11	Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers	Journal of Hematology & Oncology	Florence Coussy, Rania El Botty et al.	43
12	In vitro bone metastasis dwelling in a 3D bioengineered niche	Biomaterials	Weijing Han, Rania El Botty et al.	25
13	Interaction between IGF2‐PI3K axis and cancer‐associated‐fibroblasts promotes anal squamous carcinogenesis	International Journal of Cancer	Wulfran Cacheux, Astrid Lièvre et al.	20
14	Improvement of the anti-proliferative activity of the peptide ERα17p in MCF-7 breast cancer cells using nanodiamonds	Annales Pharmaceutiques Françaises	Fariba Némati, Rania El Botty et al.	3
15	Selumetinib-based therapy in uveal melanoma patient-derived xenografts	Oncotarget	Didier Decaudin, Rania El Botty et al.	18
16	Clinical value of R-spondins in triple-negative and metaplastic breast cancers	British Journal of Cancer	Florence Coussy, François Lallemand et al.	28
17	Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts	Journal of Proteome Research	Leslie R. Euceda, Deborah K. Hill et al.	18
18	Abstract 2087: The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma	Cancer Research	Gérald Massonnet, Rania El Botty et al.	0
19	Abstract 1687: Vandetanib as a potential new treatment for ER negative breast cancers	Cancer Research	Elisabetta Marangoni, Dalila Labiod et al.	4
20	Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts	Clinical Cancer Research	Paul Cottu, Ivan Bièche et al.	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact